Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
about
Methylseleninic acid restricts tumor growth in nude mice model of metastatic breast cancer probably via inhibiting angiopoietin-2A novel angiopoietin-2 selective fully human antibody with potent anti-tumoral and anti-angiogenic efficacy and superior side effect profile compared to Pan-Angiopoietin-1/-2 inhibitors.Plasma vascular endothelial growth factor, angiopoietin-2, and soluble angiopoietin receptor tie-2 in diabetic retinopathy: effects of laser photocoagulation and angiotensin receptor blockade.Expression of activated PIK3CA in ovarian surface epithelium results in hyperplasia but not tumor formation.Combination of interferon-alpha and 5-fluorouracil inhibits endothelial cell growth directly and by regulation of angiogenic factors released by tumor cells.Tumour vascularization: sprouting angiogenesis and beyondFatty acid binding protein 4 deficiency protects against oxygen-induced retinopathy in miceMolecular mediators of angiogenesis.Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth.The expression of Duffy antigen receptor for chemokines by epithelial ovarian cancer decreases growth potential.The alternative complement pathway regulates pathological angiogenesis in the retinaExpression of angiopoietins, Tie2 and vascular endothelial growth factor in angiogenesis and progression of hepatocellular carcinoma.Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapyEvaluation of tumor microenvironment in an animal model using a nanoparticle contrast agent in computed tomography imagingAngiogenesis and antiangiogenic agents in cervical cancer.Expression of Ets-1, Ang-2 and maspin in ovarian cancer and their role in tumor angiogenesis.Molecular profiling predicts the existence of two functionally distinct classes of ovarian cancer stroma.Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody.Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis.Intra and extravascular transmembrane signalling of angiopoietin-1-Tie2 receptor in health and disease.Association of ultrasonographic features with NGX6 expression and prognosis in invasive ductal breast carcinoma.Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer.Hypoxia-induced angiogenesis: good and evilProfiling of cytokines in human epithelial ovarian cancer ascites.Glypican-1 modulates the angiogenic and metastatic potential of human and mouse cancer cells.Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer.Major clinical research advances in gynecologic cancer in 2012.Microvascular maturity elicited in tissue treated with cytokine-loaded hyaluronan-based hydrogels.Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.Defective remodeling and maturation of the lymphatic vasculature in Angiopoietin-2 deficient mice.Breaking down the evidence for bevacizumab in advanced cervical cancer: past, present and future.Remodeling of tumor stroma and response to therapy.Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancerAngiogenesis-related pathways in the pathogenesis of ovarian cancerEvaluation of Angiopoietin-2 as a biomarker in gastric cancer: results from the randomised phase III AVAGAST trial.Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2.Inhibition of VEGF and Angiopoietin-2 to Reduce Brain Metastases of Breast Cancer Burden.Angiopoietin-1 modulates endothelial cell function and gene expression via the transcription factor FKHR (FOXO1).
P2860
Q21261285-B86B7A8B-66F9-4EEA-8BD9-FB123C64B2E0Q31110832-74331830-EB35-44CD-89BC-4622AB668320Q33209039-C1E3103B-F5AD-45B3-B66B-8F80B265D84EQ33403197-88FB2393-02C4-40D1-B7AB-817699925E9DQ33509884-B2089AC8-6482-4E3B-ABCF-C94A18220932Q33556162-AB2E6D4F-D785-4FF3-9E76-D03F1EC63F2CQ33572886-8D62A25B-399A-482F-ADF8-ECE351DFB3D6Q33639474-F3BC6E1A-4921-4C77-A2D2-7C8114280F87Q33732486-BBDFBFC4-CE15-4989-AE7B-2AD0DEAC7B99Q33750899-70A530C9-DF9D-42FE-8436-6E290584B726Q33775122-A5CA4F74-70BF-4CC2-96D1-BDA1180A188FQ33866067-77364142-F07F-42C3-9B6A-954056CBF529Q34266010-7CE9EA3B-FA6A-4B8E-AD31-E40412219DE2Q34344165-8C6462EE-181D-46C9-B4DE-B4AA54CC25C0Q34470473-F624E3A6-3F98-4A88-A5D8-C7783F237FE7Q34655335-756E3A1B-36DE-450B-B344-95B6C2B0F082Q34764817-DDFBE483-FD21-494F-AACE-38411C213B2CQ34770823-84DA5162-19C3-41CE-AD5D-CE11CD5F28C8Q35092548-895E576B-9DF9-4C4C-A0BA-647A6F8F1151Q35094484-F159F428-D663-4159-B4A1-709A7E94BDDCQ35458362-B4045E12-37DB-4106-B8BF-575A5534555EQ35919017-7FCF7060-9997-43ED-B0AA-C71F3D4A645AQ35954103-F02DD445-3EE1-4EE8-9C2F-DC85603D1C02Q36137705-5DED49B3-ACAD-47D6-B304-71C232EACCBFQ36206483-39A09833-5AFA-4DD5-B0AC-415A11D88342Q36227239-204921D8-D2D4-408F-849A-EFEC1951D104Q36449367-A019FFB4-4A6F-4330-A81F-6F3C58D27309Q36547047-F513AC09-5378-4DBD-B4E8-6A65B571BC09Q36663635-7DC51694-5EA8-40B1-B4D9-A0B21D5B71D2Q36865053-50A42187-010A-4DAB-A504-4747D7888C3CQ36876876-3FBBC16F-2E6E-44D0-B11F-08CA20BB0BA2Q36937771-C3FE426E-839E-40B3-A1E9-2FF724D9C0ABQ37016995-E50B8D9A-4EE6-407A-AC12-3BDA743CBA69Q37043828-75651556-614B-4EB9-929E-BBE31B7E486CQ37139109-9CED7FB4-E344-4BEF-ACA2-3DFFDEF32C80Q37174690-C329F0F5-7944-42DA-BB9E-0DC1C3F9E1ABQ37184436-C87236CF-71E0-4886-B129-9D5FFA964B5DQ37428029-1BE60F2E-3C57-4C01-B089-C9A37A44A115Q37747100-26720149-3BFF-46F8-A19A-E4D81FE41A8FQ38341473-8AD989F6-DD9A-4357-ACA1-181599F2C8C3
P2860
Tumor-derived vascular endothelial growth factor up-regulates angiopoietin-2 in host endothelium and destabilizes host vasculature, supporting angiogenesis in ovarian cancer.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@ast
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@en
type
label
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@ast
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@en
prefLabel
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@ast
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@en
P2093
P1433
P1476
Tumor-derived vascular endothe ...... ngiogenesis in ovarian cancer.
@en
P2093
Ann O'Brien-Jenkins
Dionyssios Katsaros
Gaoyuan Cao
George Coukos
Jin-Wan Park
Stefano Fracchioli
Stephen C Rubin
Thomas C Randall
P304
P407
P577
2003-06-01T00:00:00Z